uniQure Shares Surge to Five-Year High Following Breakthrough Huntington’s Data

The recent announcement from uniQure (NASDAQ: QURE) detailing 36-month clinical data demonstrating a significant slowing of Huntington’s disease progression has propelled the company’s stock to a five-year high. The stock more than tripled in value this past week, reflecting investor enthusiasm over the efficacy of its gene therapy candidate, AMT-130. The results indicated a statistically significant 75% reduction in disease progression, as measured by the composite Unified Huntington’s Disease Rating Scale, surpassing expectations and marking a pivotal moment for the company.

Experts, including Dr. Sarah Tabrizi from University College London, emphasized the transformative potential of these results for patients, suggesting that this therapy could extend disease-free life significantly. The positive reception among analysts has led to increased price targets for uniQure shares, with projections suggesting that AMT-130 could achieve blockbuster status, generating substantial revenue. The company is now preparing to submit a Biologics License Application to the FDA in early 2026, aiming for a commercial launch within the same year, which could further solidify its market position.